Evidence from meta-analysis supports a positive association between the XRCC3 p.Thr241Met polymorphism and the risk of bladder cancer [56–57], breast cancer [58–59], cervical cancer [60–61] and hepatocellular carcinoma [62–63]. Here, XRCC3 is linked to urinary bladder carcinoma.